Compare Humana Inc (HUM) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs Ryanair Holdings plc — how do they compare? Humana Inc trades at $406.99 (market cap $47.81B), while Ryanair Holdings plc trades at $59.37 (market cap $29.31B). The key difference: Humana Inc is the larger of the two by market cap, and Ryanair Holdings plc pays the higher dividend (1.68%). Which is the better fit depends on your goals.
| HUM | RYAAY | |
|---|---|---|
Market Cap | $47.81B | $29.31B |
Sector | Health | Industrials |
52-Week High | $409.42 | $73.82 |
52-Week Low | $163.67 | $53.24 |
Enterprise Value | $56.85B | $26.33B |
Dividend Yield | 0.89% | 1.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $398.09, down 0.48% with a bullish technical signal from moving averages. The company shows strong revenue growth to $129.66B in 2025 but faces margin compression with net income margin declining to 0.82%. Recent earnings have consistently beaten expectations, and analyst sentiment is mixed with 34% buy ratings but a consensus price target of $354.33 below current levels.
The outlook suggests cautious optimism with Medicare Advantage expansion opportunities but significant margin pressure and regulatory risks. Key investment considerations include the company's ability to achieve its 3% Medicare Advantage margin target by 2028 while navigating increased healthcare utilization costs and competitive pressures in the insurance sector.
RYAAY is trading at $58.91, down 5.85% amid broader airline sector weakness. The stock shows mixed signals with bearish technical indicators but solid fundamentals including a 13.45 P/E ratio and 13.98% net income margin. Recent Q1 2026 earnings beat expectations despite a 34% profit decline due to lower fares and higher fuel costs. Analyst consensus remains positive with 62.5% buy ratings, though technical analysis suggests near-term pressure.
RYAAY presents a value opportunity with attractive valuation metrics and strong profitability, but faces headwinds from fuel cost volatility and fare pressure. The airline's cost leadership and traffic growth provide resilience, though geopolitical risks and seasonal weakness warrant caution. Wall Street's bullish stance contrasts with current technical weakness, creating potential for recovery once sector sentiment improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
